Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
All available clinical data on anakinra in COVID-19: an updated comprehensive review
View through CrossRef
Background: Based on the investigations, cytokine-release syndrome (CRS)
play a key role in the development of acute respiratory distress
syndrome (ARDS) following SARS-CoV-2 infection. Anakinra can be
effective in the management of CRS by inhibiting IL-1 from binding to
the interleukin-1 receptors. We aimed to review the current clinical
evidence regarding the therapeutic effects of anakinra in the management
of ARDS in the context of the coronavirus disease 2019 (COVID-19).
Methods: PubMed and google scholar databases were searched and all of
the case reports, case series and RCTs were reviewed. Also, we searched
www.clinicaltrial.gov database for ongoing clinical trials of anakinra.
Results: Overall, 31 articles were found, and included 9 case report, 6
case-series and 11 RCTs. One of the reports of RCTs was not peer
reviewed. Also, ten ongoing studies were found in the clinicaltrial.gov
database searching. Conclusion: Four items have been shown to be
important to achieve the optimal therapeutic effect of anakinra in
patients withCOVID-19. These items include duration of treatment ≥ 10
days, doses of more than 100 mg, intravenous administration and early
initiation of therapy. Also, the use of corticosteroids in combination
with anakinra appears to improve clinical outcome compared to
monotherapy with anakinra.
Title: All available clinical data on anakinra in COVID-19: an updated comprehensive review
Description:
Background: Based on the investigations, cytokine-release syndrome (CRS)
play a key role in the development of acute respiratory distress
syndrome (ARDS) following SARS-CoV-2 infection.
Anakinra can be
effective in the management of CRS by inhibiting IL-1 from binding to
the interleukin-1 receptors.
We aimed to review the current clinical
evidence regarding the therapeutic effects of anakinra in the management
of ARDS in the context of the coronavirus disease 2019 (COVID-19).
Methods: PubMed and google scholar databases were searched and all of
the case reports, case series and RCTs were reviewed.
Also, we searched
www.
clinicaltrial.
gov database for ongoing clinical trials of anakinra.
Results: Overall, 31 articles were found, and included 9 case report, 6
case-series and 11 RCTs.
One of the reports of RCTs was not peer
reviewed.
Also, ten ongoing studies were found in the clinicaltrial.
gov
database searching.
Conclusion: Four items have been shown to be
important to achieve the optimal therapeutic effect of anakinra in
patients withCOVID-19.
These items include duration of treatment ≥ 10
days, doses of more than 100 mg, intravenous administration and early
initiation of therapy.
Also, the use of corticosteroids in combination
with anakinra appears to improve clinical outcome compared to
monotherapy with anakinra.
Related Results
Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19
Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19
ImportanceCOVID-19 pneumonia is often associated with hyperinflammation. The efficacy and safety of anakinra in treating patients with severe COVID-19 pneumonia and hyperinflammati...
Use of Intravenous Anakinra for Management of Pediatric Cytokine Storm Syndromes at an Academic Medical Center
Use of Intravenous Anakinra for Management of Pediatric Cytokine Storm Syndromes at an Academic Medical Center
Background: Off-label intravenous (IV) route of anakinra is increasingly recognized to enable higher and faster maximal plasma concentrations than subcutaneous route for treatment ...
Burden of the Beast
Burden of the Beast
Introduction
Throughout the COVID-19 pandemic, and its fluctuating waves of infections and the emergence of new variants, Indigenous populations in Australia and worldwide have re...
Schnitzler syndrome: response to anakinra in two cases and a review of the literature
Schnitzler syndrome: response to anakinra in two cases and a review of the literature
AbstractBackground Schnitzler syndrome is a rare disease characterized by a chronic urticarial eruption and monoclonal gammopathy, as well as clinical and laboratory signs of infl...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Analysis of Anakinra therapy for the Deficiency of Interleukin-1 Receptor Antagonist through Clinical Evidence
Analysis of Anakinra therapy for the Deficiency of Interleukin-1 Receptor Antagonist through Clinical Evidence
Deficiency of interleukin-1 receptor antagonist (DIRA) is a rare life-threatening autosomal recessive autoinflammatory disease with symptoms including but not limited to osteomyeli...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...